Literature DB >> 17981926

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

Dale McLerran1, William E Grizzle, Ziding Feng, William L Bigbee, Lionel L Banez, Lisa H Cazares, Daniel W Chan, Jose Diaz, Elzbieta Izbicka, Jacob Kagan, David E Malehorn, Gunjan Malik, Denise Oelschlager, Alan Partin, Timothy Randolph, Nicole Rosenzweig, Shiv Srivastava, Sudhir Srivastava, Ian M Thompson, Mark Thornquist, Dean Troyer, Yutaka Yasui, Zhen Zhang, Liu Zhu, O John Semmes.   

Abstract

BACKGROUND: This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer. Details of this 3-stage process have been described. This report describes the development of the algorithm and results of the blinded test for stage 1.
METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220). We also derived a validation test set from a separate, geographically diverse set of serum samples from 42 prostate cancer patients and 42 controls without prostate cancer. Aliquots were subjected to randomization and blinded analysis, and data from each laboratory site were subjected to the decision algorithm and decoded.
RESULTS: Using the data collected from the validation test set, the decision algorithm was unsuccessful in separating cancer from controls with any predictive utility. Analysis of the experimental data revealed potential sources of bias.
CONCLUSION: The ability of the decision algorithm to successfully differentiate between prostate cancer, BPH, and control samples using data derived from serum protein profiling was compromised by bias.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981926      PMCID: PMC3354530          DOI: 10.1373/clinchem.2007.091470

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  31 in total

1.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems.

Authors:  Eleftherios P Diamandis
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

2.  Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis.

Authors:  Aly Karsan; Bernhard J Eigl; Stephane Flibotte; Karen Gelmon; Philip Switzer; Patricia Hassell; Dorothy Harrison; Jennifer Law; Malcolm Hayes; Moira Stillwell; Zhen Xiao; Thomas P Conrads; Timothy Veenstra
Journal:  Clin Chem       Date:  2005-06-10       Impact factor: 8.327

3.  SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions.

Authors:  Avram Z Traum; Meghan P Wells; Manuel Aivado; Towia A Libermann; Marco F Ramoni; Asher D Schachter
Journal:  Proteomics       Date:  2006-03       Impact factor: 3.984

4.  Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling.

Authors:  Sen-Yung Hsieh; Ren-Kung Chen; Yi-Hsin Pan; Hai-Lun Lee
Journal:  Proteomics       Date:  2006-05       Impact factor: 3.984

5.  Serum proteomic patterns for detection of prostate cancer.

Authors:  Emanuel F Petricoin; David K Ornstein; Cloud P Paweletz; Ali Ardekani; Paul S Hackett; Ben A Hitt; Alfredo Velassco; Christian Trucco; Laura Wiegand; Kamillah Wood; Charles B Simone; Peter J Levine; W Marston Linehan; Michael R Emmert-Buck; Seth M Steinberg; Elise C Kohn; Lance A Liotta
Journal:  J Natl Cancer Inst       Date:  2002-10-16       Impact factor: 13.506

6.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

7.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer.

Authors:  Jinong Li; Zhen Zhang; Jason Rosenzweig; Young Y Wang; Daniel W Chan
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

8.  An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers.

Authors:  Yutaka Yasui; Dale McLerran; Bao-Ling Adam; Marcy Winget; Mark Thornquist; Ziding Feng
Journal:  J Biomed Biotechnol       Date:  2003

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  the need for review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis.

Authors:  William E Grizzle; O John Semmes; William Bigbee; Liu Zhu; Gunjan Malik; Denise K Oelschlager; Barkha Manne; Upender Manne
Journal:  Cancer Inform       Date:  2005
View more
  40 in total

1.  Issues in collecting, processing and storing human tissues and associated information to support biomedical research.

Authors:  William E Grizzle; Walter C Bell; Katherine C Sexton
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling.

Authors:  Simone Nicolardi; Magnus Palmblad; Hans Dalebout; Marco Bladergroen; Rob A E M Tollenaar; André M Deelder; Yuri E M van der Burgt
Journal:  J Am Soc Mass Spectrom       Date:  2010-05-12       Impact factor: 3.109

3.  Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

Authors:  Henrik Ryberg; Jiyan An; Samuel Darko; Jonathan Llyle Lustgarten; Matt Jaffa; Vanathi Gopalakrishnan; David Lacomis; Merit Cudkowicz; Robert Bowser
Journal:  Muscle Nerve       Date:  2010-07       Impact factor: 3.217

4.  Bringing diagnostic technologies to the clinical laboratory: Rigor, regulation, and reality.

Authors:  Gordon Whiteley
Journal:  Proteomics Clin Appl       Date:  2008       Impact factor: 3.494

5.  Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.

Authors:  Bert Dhondt; Elise De Bleser; Tom Claeys; Sarah Buelens; Nicolaas Lumen; Jo Vandesompele; Anneleen Beckers; Valerie Fonteyne; Kim Van der Eecken; Aurélie De Bruycker; Jérôme Paul; Pierre Gramme; Piet Ost
Journal:  World J Urol       Date:  2018-12-21       Impact factor: 4.226

Review 6.  Challenges for biomarker discovery in body fluids using SELDI-TOF-MS.

Authors:  Muriel De Bock; Dominique de Seny; Marie-Alice Meuwis; Jean-Paul Chapelle; Edouard Louis; Michel Malaise; Marie-Paule Merville; Marianne Fillet
Journal:  J Biomed Biotechnol       Date:  2009-12-06

7.  Biomarker Validation for Aging: Lessons from mtDNA Heteroplasmy Analyses in Early Cancer Detection.

Authors:  Peter E Barker; Mahadev Murthy
Journal:  Biomark Insights       Date:  2009-11-27

8.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Authors:  Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

9.  Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer.

Authors:  Lynn M Amon; Wendy Law; Matthew P Fitzgibbon; Jennifer A Gross; Kathy O'Briant; Amelia Peterson; Charles Drescher; Daniel B Martin; Martin McIntosh
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

10.  Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer.

Authors:  Qi Wang; Jing Shen; Zhen-fu Li; Jian-zheng Jie; Wen-yue Wang; Jin Wang; Zhong-tao Zhang; Zhi-xia Li; Li Yan; Jin Gu
Journal:  BMC Cancer       Date:  2009-08-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.